Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluzoparil + anlotinib
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of fluzoparil and anlotinib, currently being investigated for the treatment of extensive-stage small cell lung cancer (ES-SCLC) following the failure of first-line platinum-based chemotherapy. Fluzoparil is a potent, selective inhibitor of poly(ADP-ribose) polymerase (PARP) 1 and 2, which impairs DNA damage repair and induces synthetic lethality in tumors with DNA repair deficiencies. Anlotinib is a multi-targeted tyrosine kinase inhibitor that suppresses tumor angiogenesis and proliferation by inhibiting VEGFR1-3, FGFR1-4, PDGFRα/β, and c-Kit. The STAMP study, led by investigator Liu Zhenhua, evaluates the efficacy and safety of this dual-targeted approach in patients who have progressed after standard treatment.
- Other names
- Fluzopalil and AnlotinibFluzoparil and Anlotinib
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on fluzoparil + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluzoparil + anlotinib.